6-K

IceCure Medical Ltd. (ICCM)

6-K 2024-08-06 For: 2024-08-06
View Original
Added on April 11, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: August 2024

Commission File Number: 001-40753


ICECURE MEDICAL LTD.

(Translation of registrant’s name intoEnglish)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F


CONTENTS

On July 16, 2024, IceCure Medical Ltd. (the “Company”) issued a Report of Foreign Private Issuer on Form 6-K announcing that it intended to hold a Special General Meeting of its shareholders on August 21, 2024 (the “Meeting”), along with the related proxy materials.

On August 4, 2024, in light of communications with shareholders of the Company, the Company’s Board of Directors decided to cancel the Meeting and will reevaluate equity-based compensation matters in advance of a future meeting of shareholders.

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660 and 333-267272) and Form S-8 (Registration Nos. 333-270982, 333-264578 and 333-262620), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

ICECURE MEDICAL LTD.
Date: August 6, 2024 By: /s/ Eyal Shamir
Name Eyal Shamir
Title: Chief Executive Officer
2